The effect of vaccination against the COVID-19 on the course and outcomes of a new coronavirus infection: a retrospective analysis of laboratory and clinical indicators of hospitalized patients

Abstract

BACKGROUND: The Gam-COVID-Vac vaccine was proven effective in preventing the severe course and adverse outcomes of COVID-19 during different periods of the pandemic. However, the effect of vaccination on laboratory marker levels in hospitalized patients during the spread of the omicron variant of SARS-CoV-2 has not been sufficiently studied.

AIM: To assess the effect of vaccination on the severity and outcomes of COVID-19 in hospitalized patients during the dominance of the SARS-CoV-2 omicron variant in Russia.

MATERIALS AND METHODS: This case–control study included adult patients diagnosed with COVID-19 (U07.1) and hospitalized in infectious hospitals in Moscow between February 1, 2022, and July 31, 2022 (n=119). The main group included individuals vaccinated with two doses of Sputnik V vaccine (n=59). The control group included individuals who were not vaccinated (n=60). The median patient age was 66 [interquartile range, 41–66] years, and 58.8% were female. The chi-square test for categorical variables and the Mann–Whitney test for continuous variables were used for the analysis. P-values <0.05 were considered statistically significant.

RESULTS: Viral pneumonia was less likely to develop in the vaccinated group than in the unvaccinated group (46.7% and 18.6%, respectively, p = 0.007). The proportion of patients without lung damage (0 CT-severity scores) in the vaccinated group (72.0%) was significantly higher than that in the unvaccinated group (42.9%) (p=0.003). In the vaccinated group, the levels of C-reactive protein on admission were lower (29.1 [7.4–68.6] mg/L and 75.1 [32.4–104.0] mg/L, p <0.001), and the highest level was recorded during hospitalization (38.2 [12.0–84.0] mg/L and 92.2 [45.3–137.4] mg/L, p <0.001). The D-dimer levels before discharge were lower in the group of patients vaccinated <6 months ago than in the unvaccinated group (157.0 [107.0–297.0] ng/mL and 316.0 [125.0–556.0] ng/mL, respectively, p = 0.014). The frequency of deaths in the control group (11.7%) was 6.9 times higher than that in the main group (1.7%) (p = 0.030).

CONCLUSIONS: Completion of the primary vaccination course of Sputnik V vaccine resulted in lower levels of prognostic markers of severe COVID-19 (C-reactive protein and D-dimer) and a decrease in the frequency of pulmonary and fatal outcomes than in the unvaccinated group during the dominance of the omicron variant of SARS-CoV-2.

Keywords

SARS-CoV-2 / COVID-19 / vaccination / outcomes / C-reactive protein / D-dimer

References

[1] Weekly epidemiological update on COVID-19 — 4 January 2023. World Health Organization [Internet]. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---4-january-2023.

[2] Weekly epidemiological update on COVID-19 — 4 January 2023 // World Health Organization [Internet]. Режим доступа: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---4-january-2023.

[3] Stopcoronavirus.rf [Internet]. (In Russ). Available at: https://стопкоронавирус.рф.

[4] Стопкоронавирус.рф [интернет]. Режим доступа: https://стопкоронавирус.рф.

[5] Tiruneh SA, Tesema ZT, Azanaw MM, Angaw DA. The effect of age on the incidence of COVID-19 complications: A systematic review and meta-analysis. Syst Rev. 2021;10(1):80. doi: 10.1186/s13643-021-01636-2

[6] Tiruneh S.A., Tesema Z.T., Azanaw M.M., Angaw D.A. The effect of age on the incidence of COVID-19 complications: A systematic review and meta-analysis // Syst Rev. 2021. Vol. 10, N 1. P. 80. doi: 10.1186/s13643-021-01636-2

[7] Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021;3(3):CD013879. doi: 10.1002/14651858.CD013879

[8] Pellicori P., Doolub G., Wong C.M., et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies // Cochrane Database Syst Rev. 2021. Vol. 3, N 3. P. CD013879. doi: 10.1002/14651858.CD013879

[9] Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76(10):970–979. doi: 10.1136/thoraxjnl-2020-215383

[10] Tan B.K., Mainbourg S., Friggeri A., et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis // Thorax. 2021. Vol. 76, N 10. P. 970–979. doi: 10.1136/thoraxjnl-2020-215383

[11] Sahranavard M, Akhavan Rezayat A, Zamiri Bidary M, et al. Cardiac Complications in COVID-19: A Systematic Review and Meta-analysis. Arch Iran Med. 2021;24(2):152–163. doi: 10.34172/aim.2021.24

[12] Sahranavard M., Akhavan Rezayat A., Zamiri Bidary M., et al. Cardiac Complications in COVID-19: A Systematic Review and Meta-analysis // Arch Iran Med. 2021. Vol. 24, N 2. P. 152–163. doi: 10.34172/aim.2021.24

[13] Zhao YH, Zhao L, Yang XC, Wang P. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): A systematic review and meta-analysis. Rev Cardiovasc Med. 2021;22(1):159–165. doi: 10.31083/j.rcm.2021.01.238

[14] Zhao Y.H., Zhao L., Yang X.C., Wang P. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): A systematic review and meta-analysis // Rev Cardiovasc Med. 2021. Vol. 22, N 1. P. 159–165. doi: 10.31083/j.rcm.2021.01.238

[15] Raina R, Mahajan ZA, Vasistha P, et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review. Blood Purif. 2022;51(3):199–212. doi: 10.1159/000514940

[16] Raina R., Mahajan Z.A., Vasistha P., et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review // Blood Purif. 2022. Vol. 51, N 3. P. 199–212. doi: 10.1159/000514940

[17] Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107–108. doi: 10.1136/bmjebm-2020-111536

[18] Malik P., Patel U., Mehta D., et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis // BMJ Evid Based Med. 2021. Vol. 26, N 3. P. 107–108. doi: 10.1136/bmjebm-2020-111536

[19] Wang L, Yang LM, Pei SF, et al. CRP, SAA, LDH, and DD predict poor prognosis of coronavirus disease (COVID-19): a meta-analysis from 7739 patients. Scand J Clin Lab Invest. 2021;81(8):679–686. doi: 10.1080/00365513.2021.2000635

[20] Wang L., Yang L.M., Pei S.F., et al. CRP, SAA, LDH, and DD predict poor prognosis of coronavirus disease (COVID-19): a meta-analysis from 7739 patients // Scand J Clin Lab Invest. 2021. Vol. 81, N 8. P. 679–686. doi: 10.1080/00365513.2021.2000635

[21] Matthay MA, Arabi Y, Arroliga AC, et al. A New Global Definition of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine. 2024;209(1):37–47. doi: 10.1164/rccm.202303-0558WS

[22] Matthay M.A., Arabi Y., Arroliga A.C., et al. A New Global Definition of Acute Respiratory Distress Syndrome // American Journal of Respiratory and Critical Care Medicine. 2024. Vol. 209, N 1. P. 37–47. doi: 10.1164/rccm.202303-0558WS

[23] Crimi C, Murphy P, Patout M, Sayas J, Winck JC. Lessons from COVID-19 in the management of acute respiratory failure. Breathe (Sheff). 2023;19(1):230035. doi: 10.1183/20734735.0035-2023

[24] Crimi C., Murphy P., Patout M., Sayas J., Winck J.C. Lessons from COVID-19 in the management of acute respiratory failure // Breathe (Sheff). 2023. Vol. 19, N 1. P. 230035. doi: 10.1183/20734735.0035-2023

[25] Zheng C, Shao W, Chen X, et al. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis. Int J Infect Dis. 2021;114:252–260. doi: 10.1016/j.ijid.2021.11.009

[26] Zheng C., Shao W., Chen X., et al. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis // Int J Infect Dis. 2021. Vol. 114. P. 252–260. doi: 10.1016/j.ijid.2021.11.009

[27] Patel AK, Patel D, Shevkani M, et al. COVID-19 patients’ clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. Indian J Med Microbiol. 2023;41:28–32. doi: 10.1016/j.ijmmb.2022.12.004

[28] Patel A.K., Patel D., Shevkani M., et al. COVID-19 patients’ clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India // Indian J Med Microbiol. 2023. Vol. 41. P. 28–32. doi: 10.1016/j.ijmmb.2022.12.004

[29] Fatima S, Zafar A, Afzal H, et al. COVID-19 infection among vaccinated and unvaccinated: Does it make any difference? PloS one. 2022;17(7):e0270485. doi: 10.1371/journal.pone.0270485

[30] Fatima S., Zafar A., Afzal H., et al. COVID-19 infection among vaccinated and unvaccinated: Does it make any difference? // PloS one. 2022. Vol. 17, N 7. P. e0270485. doi: 10.1371/journal.pone.0270485

[31] Barchuk A, Bulina A, Cherkashin M, et al. Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg: A test-negative case-control study. Respir Res. 2022;23(1):276. doi: 10.1186/s12931-022-02206-3

[32] Barchuk A., Bulina A., Cherkashin M., et al. Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg // Respir Res. 2022. Vol. 23, N 1. P. 276. doi: 10.1186/s12931-022-02206-3

[33] Shkoda AS, Gushchin VA, Ogarkova DA, et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines (Basel). 2022;10(6):938. doi: 10.3390/vaccines10060938

[34] Shkoda A.S., Gushchin V.A., Ogarkova D.A., et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance // Vaccines. 2022. Vol. 10, N 6. P. 938. doi: 10.3390/vaccines10060938

[35] Wang J, Choy KW, Lim HY, Ho P. Impaired Fibrinolytic Potential Predicts Oxygen Requirement in COVID-19. J Pers Med. 2022;12(10):1711. doi: 10.3390/jpm12101711

[36] Wang J., Choy K.W., Lim H.Y., Ho P. Impaired Fibrinolytic Potential Predicts Oxygen Requirement in COVID-19 // J Pers Med. 2022. Vol. 12, N 10. P. 1711. doi: 10.3390/jpm12101711

[37] Feldblum IV, Repin TM, Devyatkov MY, et al. Preventive Efficacy of Domestic Vaccines against a New Coronavirus Infection in the Immunization of Employees of Medical Organizations. Epidemiology and Vaccinal Prevention. 2023;22(1):22–27. (In Russ). doi: 10.31631/2073-3046-2023-22-1-22-27

[38] Фельдблюм И.В., Репин Т.М., Девятков М.Ю., и др. Профилактическая эффективность отечественных вакцин против новой коронавирусной инфекции при иммунизации сотрудников медицинских организаций // Эпидемиология и Вакцинопрофилактика. 2023. Т. 22, № 1. C. 22–27. doi: 10.31631/2073-3046-2023-22-1-22-27

[39] Nikonov EL, Boychenko YuYa, Kuznetsova AV. Effectiveness of Gam-COVID-Vac vaccine in the Khabarovsk region from october 2020 to june 2021 based on registers data. Profilakticheskaya Meditsina. 2021;24(11):62–69. (In Russ). doi: 10.17116/profmed20212411162

[40] Никонов Е.Л., Бойченко Ю.Я., Кузнецова А.В. Эффективность использования вакцины Гам-КОВИД-Вак в Хабаровском крае с октября 2020 г. по июнь 2021 г. по данным регистров // Профилактическая медицина. 2021. Т. 24, № 11. C. 62–69. doi: 10.17116/profmed20212411162

[41] Molchanova ZhR, Babura EA, Zaguzov VS, Lyalina LV. COVID-19 Epidemic in the Kaliningrad Region: Incidence and Infection Control Measures. Public Health and Life Environment — PH&LE. 2023;31(3): 52–63. (In Russ). doi: 10.35627/2219-5238/2023-31-3-52-63

[42] Молчанова Ж.Р., Бабура Е.А., Загузов В.С., Лялина Л.В. Эпидемия COVID-19 в Калининградской области: меры борьбы и профилактики // Здоровье населения и среда обитания — ЗНиСО. 2023. Т. 31, № 3. C. 52–63. doi: 10.35627/2219-5238/2023-31-3-52-63

[43] Poteshkina NG, Krylova NS, Ibragimova AM, et al. Respiratory and thromboembolic complications of COVID-19-associated pneumonia in COVID-19 vaccinated patients. Lechebnoe delo. 2023;(2):81–86. (In Russ). doi: 10.24412/2071-5315-2023-12883

[44] Потешкина Н.Г., Крылова Н.С., Ибрагимова А.М., и др. Респираторные и тромбоэмболические осложнения COVID-19-ассоциированной пневмонии у пациентов, вакцинированных против COVID-19 // Лечебное дело. 2023. № 2. С. 81–86. doi: 10.24412/2071-5315-2023-12883

[45] Linets YuP, Artyukhov SV, Kazantsev AN, et al. COVID-19 Course in Vaccinated Patients. Russian Sklifosovsky Journal “Emergency Medical Care”. 2021;10(4):636–641. (In Russ). doi: 10.23934/2223-9022-2021-10-4-636-641

[46] Линец Ю.П., Артюхов С.В., Казанцев А.Н., и др. Течение COVID-19 у вакцинированных пациентов // Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2021. Т. 10, № 4. C. 636–641. doi: 10.23934/2223-9022-2021-10-4-636-641

[47] Moiseeva AG, Serova NYu, Shaikhutdinova RA, et al. Thrombosis in unvaccinated and Gam-COVID-Vac-vaccinated patients with COVID-19. Russian Journal of Cardiology. 2022;27(7):5091. (In Russ). doi: 10.15829/1560-4071-2022-5091

[48] Моисеева А.Г., Серова Н.Ю., Шайхутдинова Р.А., и др. Тромбозы у невакцинированных и вакцинированных пациентов вакциной «Спутник V» (Гам-КОВИД-Вак), инфицированных COVID-19 // Российский кардиологический журнал. 2022. Т. 27, № 7. C. 5091. doi: 10.15829/1560-4071-2022-5091

[49] Kostinov MP, Zhang C, Khrapunova IA, et al. Time-dependent changes of platelet and D-dimer parameters in vaccinated versus non-immunized COVID-19 patients. Russian Journal of Immunology. 2023;26(4):627–632. doi: 10.46235/1028-7221-13983-TDC

[50] Костинов М.П., Чжан Ч., Храпунова И.А., и др. Динамика показателей тромбоцитов и D-димера вакцинированных лиц, заболевших COVID-19, по сравнению с не иммунизированными против этой инфекции // Российский иммунологический журнал. 2023. Т. 26, № 4. C. 627–632. doi: 10.46235/1028-7221-13983-TDC

[51] Tracking of hCoV-19 Variants. GISAID [Internet]. Available at: https://gisaid.org/hcov19-variants/.

[52] Tracking of hCoV-19 Variants // GISAID [Internet]. Режим доступа: https://gisaid.org/hcov19-variants.

[53] Khare S, Gurry C, Freitas L, et al. GISAID’s Role in Pandemic Response. China CDC Weekly. 2021;3(49):1049–1051. doi: 10.46234/ccdcw2021.255

[54] Khare S., Gurry C., Freitas L., et al. GISAID’s Role in Pandemic Response // China CDC Weekly. 2021. Vol. 3, N 49. P. 1049–1051. doi: 10.46234/ccdcw2021.255

[55] Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022;20:200. doi: 10.1186/s12916-022-02397-y

[56] Zeng B., Gao L., Zhou Q., Yu K., Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis // BMC Med. 2022. Vol. 20. P. 200. doi: 10.1186/s12916-022-02397-y

[57] Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761. doi: 10.1136/bmj-2021-069761

[58] Lauring A.S., Tenforde M.W., Chappell J.D., et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study // BMJ. 2022. Vol. 376. P. e069761. doi: 10.1136/bmj-2021-069761

[59] Zizza A, Sedile R, Bagordo F, et al. Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination. Vaccines. 2023;11(8):1342. doi: 10.3390/vaccines11081342

[60] Zizza A., Sedile R., Bagordo F., et al. Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination // Vaccines. 2023. Vol. 11, N 8. P. 1342. doi: 10.3390/vaccines11081342

RIGHTS & PERMISSIONS

Eco-vector